热门资讯> 正文
Eliem Therapeutics GAAP每股收益为-1.81美元
2024-08-15 00:18
- Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$1.81.
- Cash and cash equivalents were $223.1 million as of June 30, 2024, as compared to cash, cash equivalents, and marketable securities of $106.8 million as of December 31, 2023.
More on Eliem Therapeutics
- Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
- Financial information for Eliem Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
